Javascript must be enabled to continue!
Early TIPS versus endoscopic therapy for secondary prophylaxis after management of acute esophageal variceal bleeding in cirrhotic patients: a meta‐analysis of randomized controlled trials
View through CrossRef
AbstractBackground and aimsAmerican College of Gastroenterology and American Association for the Study of Liver Disease guidelines recommend endoscopic and pharmacologic treatment for esophageal variceal bleed. Transjugular intrahepatic portosystemic shunt (TIPS) placement is reserved for cases of therapeutic failure. Several studies have suggested improved prevention of rebleeding and improved survival without excess hepatic encephalopathy in patients who receive TIPS within the first 5 days after bleeding (early TIPS). In this meta‐analysis, we evaluated the safety and efficacy of early TIPS versus endoscopic therapy for secondary prophylaxis after acute esophageal variceal bleeding in cirrhotic patients.MethodsPubmed, Medline, Embase, ClinicalTrials.gov, and ISI Web of Science were searched for randomized controlled trials that compared early TIPS to endoscopic therapy. The primary outcome was mortality at 1 year; secondary outcomes were rebleeding and hepatic encephalopathy at 1 year.ResultsNine randomized controlled trials involving 608 cirrhotic patients were identified. Early TIPS was associated with a significant risk reduction in 1‐year mortality (RR, 0.68; 95% CI, 0.49‐0.96; P = 0.03) and 1‐year incidence of variceal rebleeding (RR, 0.28; 95% CI, 0.20‐0.40; P < 0.001) without significant heterogeneity among studies (I2 = 30% and 47%, respectively). No significant difference in the incidence of hepatic encephalopathy at 1 year was observed (RR, 1.36; 95% CI, 0.72‐2.56; P = 0.34); however, there was significant heterogeneity among studies (I2 = 68%).ConclusionTIPS placed within 5 days after a major esophageal variceal hemorrhage is superior to endoscopic treatment in reducing subsequent bleeding. Early TIPS placement is also associated with superior 1‐year survival without significantly increasing the incidence of hepatic encephalopathy.
Title: Early TIPS versus endoscopic therapy for secondary prophylaxis after management of acute esophageal variceal bleeding in cirrhotic patients: a meta‐analysis of randomized controlled trials
Description:
AbstractBackground and aimsAmerican College of Gastroenterology and American Association for the Study of Liver Disease guidelines recommend endoscopic and pharmacologic treatment for esophageal variceal bleed.
Transjugular intrahepatic portosystemic shunt (TIPS) placement is reserved for cases of therapeutic failure.
Several studies have suggested improved prevention of rebleeding and improved survival without excess hepatic encephalopathy in patients who receive TIPS within the first 5 days after bleeding (early TIPS).
In this meta‐analysis, we evaluated the safety and efficacy of early TIPS versus endoscopic therapy for secondary prophylaxis after acute esophageal variceal bleeding in cirrhotic patients.
MethodsPubmed, Medline, Embase, ClinicalTrials.
gov, and ISI Web of Science were searched for randomized controlled trials that compared early TIPS to endoscopic therapy.
The primary outcome was mortality at 1 year; secondary outcomes were rebleeding and hepatic encephalopathy at 1 year.
ResultsNine randomized controlled trials involving 608 cirrhotic patients were identified.
Early TIPS was associated with a significant risk reduction in 1‐year mortality (RR, 0.
68; 95% CI, 0.
49‐0.
96; P = 0.
03) and 1‐year incidence of variceal rebleeding (RR, 0.
28; 95% CI, 0.
20‐0.
40; P < 0.
001) without significant heterogeneity among studies (I2 = 30% and 47%, respectively).
No significant difference in the incidence of hepatic encephalopathy at 1 year was observed (RR, 1.
36; 95% CI, 0.
72‐2.
56; P = 0.
34); however, there was significant heterogeneity among studies (I2 = 68%).
ConclusionTIPS placed within 5 days after a major esophageal variceal hemorrhage is superior to endoscopic treatment in reducing subsequent bleeding.
Early TIPS placement is also associated with superior 1‐year survival without significantly increasing the incidence of hepatic encephalopathy.
Related Results
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Association of Anticoagulant Therapy with Bleeding in Patients with Chronic Liver Disease: A Case-Cross over Study Using the National Veterans Health Administration Database
Association of Anticoagulant Therapy with Bleeding in Patients with Chronic Liver Disease: A Case-Cross over Study Using the National Veterans Health Administration Database
Background:
Patients with chronic liver disease (CLD) are at a higher risk of venous thromboembolism (VTE) i.e., deep venous thrombosis or pulmonary embolism {Amb...
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
BackgroundA clinical dilemma exists in patients with CKD, ESKD, and after kidney transplantation, as they face concurrent risks of both thromboembolic and hemorrhagic complications...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Outcomes in Cirrhotic Patients Receiving Transjugular Intrahepatic Portosystemic Shunt (TIPS) Versus Repeat Paracentesis for Recurrent Ascites
Outcomes in Cirrhotic Patients Receiving Transjugular Intrahepatic Portosystemic Shunt (TIPS) Versus Repeat Paracentesis for Recurrent Ascites
Abstract
Purpose: Many cirrhotic patients who cannot undergo liver transplantation are symptomatically treated for recurrent ascites with paracenteses and/or transjugular i...
Efficacy of propranolol versus carvedilol in prophylaxis of variceal bleeding: Randomized clinical trial.
Efficacy of propranolol versus carvedilol in prophylaxis of variceal bleeding: Randomized clinical trial.
Objective: To compare the efficacy of carvedilol and propranolol for prophylaxis of variceal bleeding in cirrhotic patients. Study Design: Randomized Controlled Trial. Setting: Dep...
PREDICTORS OF RE-BLEEDING AFTER OESOPHAGEAL VARICEAL BANDING IN CIRRHOTIC PATIENTS AT 4 WEEKS
PREDICTORS OF RE-BLEEDING AFTER OESOPHAGEAL VARICEAL BANDING IN CIRRHOTIC PATIENTS AT 4 WEEKS
Background: Acute upper gastrointestinal bleeding is a serious complication in cirrhotic patients. Without recommended management, recurrent bleeding happens in 30-40% within the n...

